Sugi Predict

Sugi Predict / Compounds / SCHEMBL564441

SCHEMBL564441

SCHEMBL564441

CC[C@@H](C(N)=O)N1CC(COS(C)(=O)=O)CC1=O

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA3 P07451 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ CA6 P23280 1/20 0.43
▸ CA5A P35218 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ CA13 Q8N1Q1 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ CA5B Q9Y2D0 1/20 0.43
▸ BRD4 O60885 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073937 0.90 LMNA (0.47) LMNACA12CA1CA2CA3
SCHEMBL6030095 0.88 LMNA (0.47) LMNACA12CA1CA2CA3
SCHEMBL4497051 0.88 LMNA (0.47) LMNACA12CA1CA2CA3
SCHEMBL564553 0.84 LMNA (0.47) LMNACA12CA1CA2CA3
SCHEMBL563206 0.84 LMNA (0.47) LMNACA12CA1CA2CA3
SCHEMBL564440 0.84 LMNA (0.47) LMNACA12CA1CA2CA3
SCHEMBL563757 0.83 LMNA (0.43) LMNACA12CA1CA2CA3
SCHEMBL2513350 0.83 LMNA (0.46) LMNACA12CA1CA2CA3
SCHEMBL25384229 0.83 LMNA (0.37) LMNACA12CA1CA2CA3
SCHEMBL564353 0.83 LMNA (0.37) LMNACA12CA1CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11231424-B2 Levetiracetam immunoassays ARK DIAGNOSTICS, INC. (US) 2022-01-25 — — US disclosed
US-20200240991-A1 Levetiracetam Immunoassays ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT 2020-07-30 — — US disclosed
US-20150044693-A1 Levetiracetam Immunoassays ARK DIAGNOSTICS, INC. 2015-02-12 — — US disclosed
US-20150044693-A1 Levetiracetam Immunoassays ARK DIAGNOSTICS, INC. 2015-02-12 — — US disclosed
US-8841136-B2 Levetiracetam immunoassays ARK DIAGNOSTICS, INC. (US) 2014-09-23 — — US disclosed
US-8841136-B2 Levetiracetam immunoassays ARK DIAGNOSTICS, INC. (US) 2014-09-23 — — US disclosed
EP-2349335-B1 LEVETIRACETAM IMMUNOASSAYS ARK DIAGNOSTICS INC (US) 2013-08-07 — — EP disclosed
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 — — US disclosed
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 — — US disclosed
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 — — US disclosed
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses DIFFERDING EDMOND (BE) 2005-08-04 — — US disclosed
US-20050171188-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2005-08-04 — — US disclosed
US-6911461-B2 For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse UCB, S.A. (BE) 2005-06-28 — — US disclosed
US-6806287-B2 NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE UCB, S.A. (BE) 2004-10-19 — — US disclosed
EP-1452524-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-09-01 — — EP disclosed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 — — US disclosed
EP-1447399-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-08-18 — — EP disclosed
US-20040116507-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2004-06-17 — — US disclosed
US-20040087646-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2004-05-06 — — US disclosed
US-20030120080-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2003-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 LMNA 3694/4885CA12 4426/4885CA1 2098/4885
US-20050171188-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 LMNA 3694/4885CA12 4426/4885CA1 2098/4885
US-20030120080-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, CYP1A2, OGDH LMNA 3771/4885CA12 4126/4885CA1 1842/4885
US-20200240991-A1 Levetiracetam Immunoassays GABRG1, GABRA6, LY96 LMNA 1758/4885CA12 727/4885CA1 192/4885
US-20040087646-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, CYP1A2, OGDH LMNA 3802/4885CA12 4185/4885CA1 1667/4885
US-11231424-B2 Levetiracetam immunoassays GABRG1, GABRA6, LY96 LMNA 1758/4885CA12 727/4885CA1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.